Big Pharma, UK Universities Launch 'Unique' Early Drug Development Fund
This article was originally published in Scrip
Executive Summary
AstraZeneca plc, GlaxoSmithKline plc and Johnson & Johnson are investing £30m between them into a new fund aimed at advancing academic therapeutic research from three leading universities.
You may also be interested in...
Family Offices Boost Life Sciences Partners’s Over-Subscribed Fifth Fund
Family offices are increasing their exposure to Europe’s life sciences sector by investing in venture capital funds, including the just-closed over-subscribed fifth fund from Life Sciences Partners.
Building The Talent Pipeline Starts With Access For All
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
Snapshot: October Highlights
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
Need a specific report? 1000+ reports available
Buy Reports